Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2026-04-13 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于召开2025年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an investor performance briefing meeting (业绩说明会) for the 2025 annual report and 2026 first quarter report. It provides details on the meeting time, location, participation method, and contact information. It does not contain the actual financial results or detailed financial statements but rather informs investors about the upcoming event where such information will be discussed. The document length is short (1466 characters) and it is clearly an announcement of a meeting rather than the report itself. Therefore, it fits best into the category of Investor Presentation (IP), as it is a detailed presentation event for investors focusing on financials and company performance.
2026-04-13 Chinese
长春百克生物科技股份公司2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025年度业绩快报公告" which translates to "2025 Annual Performance Express Report Announcement." It contains preliminary financial data and key performance indicators for the year 2025, including revenue, profit, net income, and asset figures. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be in the 2025 Annual Report. The document is relatively short (2159 characters) and serves as a quick earnings summary rather than a full detailed financial report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is an initial announcement of yearly financial results, which fits the definition of an Earnings Release (ER). FY 2025
2026-02-26 Chinese
长春百克生物科技股份公司2025年年度业绩预亏公告
Earnings Release Classification · 95% confidence The document is titled as a "2025 Annual Performance Loss Forecast Announcement" from Changchun Baike Biotechnology Co., Ltd. It provides preliminary profit forecast data for the full fiscal year 2025, including expected net loss ranges and reasons for the performance decline. It explicitly states that the forecast data is unaudited and that the final audited data will be disclosed in the formal 2025 annual report. The document is relatively short (1679 characters) and serves as a performance forecast announcement rather than a full annual report or audited financial statement. It does not contain comprehensive financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a forward-looking earnings guidance announcement. This type of document fits best under the Earnings Release (ER) category, which covers initial announcements of quarterly or periodical financial results or forecasts with key highlights only. FY 2025
2026-01-16 Chinese
长春百克生物科技股份公司关于更换持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for the company 百克生物. It details the replacement of a sponsor representative and includes a brief biography of the new representative. There is no financial data, no report or presentation content, and no mention of voting results or dividends. This is a management or board-related announcement about personnel changes in the company's sponsor representatives, which aligns with Board/Management Information filings. The document length is short and it is not a report or a certification, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the best fit is Board/Management Information (MANG).
2025-12-25 Chinese
长春百克生物科技股份公司关于选举第六届董事会职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a staff representative director to the company's sixth board of directors. It includes details about the election process, the qualifications of the elected director, and compliance with relevant laws and regulations. There is no financial data, audit information, or report content. The document is clearly about board/management information, specifically about a change or appointment in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on this announcement, not a full report or presentation.
2025-11-14 Chinese
长春百克生物科技股份公司关于自愿披露吸附无细胞百（二组分）白破联合疫苗（成人及青少年用）临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Changchun Baike Biotechnology Co., Ltd. regarding the approval of a clinical trial application for a new vaccine by the National Medical Products Administration. It includes details about the approval notice, the vaccine description, potential impact on the company, and risk warnings. The document is short (1426 characters) and does not contain financial data, financial statements, or detailed financial analysis. It is an announcement of a regulatory approval event related to clinical trials, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.